Rockwell Medical Technologies (NASDAQ: RMTI) reported Q4 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $14.8 million versus the consensus estimate of $13.8 million.

Q4 2017 Financial Highlights

• Sales were $14.8 million, $1.4 million or 10.8% higher than Q4 2016
• The company reported a negative gross profit of ($1.2) million compared to $2.0 million gross profit in Q4 2016 due to a $3.3 million reserve incurred for expiring pharmaceutical inventory.
• SG&A expense was $5.9 million compared to $6.0 million in Q4 2016.
• R&D expense was $2.1 million compared to $1.2 million in Q4 2016.
• Net loss was ($9.0) million or ($0.18) per share compared to a ($5.1) million net loss or ($0.10) per share in Q4 2016.
• Cash and investments were $33.1 million as of December 31, 2017.
• Net working capital was $39.7 million as of December 31, 2017.

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.